Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd is positioned favorably due to a significant increase in its equipment utilization rate, exceeding 50% since the introduction of strategic investments. The company is capitalizing on recent FDA approvals, particularly with the Neurolief Proliv™Rx device, which enhances its revenue potential and elevates its overall valuation metrics. Furthermore, BrainsWay's growing acceptance of pay-per-use models and its expanding presence among neurologist prescribers indicate strong prospects for accelerated revenue growth in the evolving medtech landscape.

Bears say

BrainsWay Ltd faces several fundamental risks that contribute to a negative outlook on its stock. These risks include a slower-than-projected uptake of its Deep TMS systems, which could hinder revenue growth, as well as challenges in expanding reimbursement and market access that may limit patient adoption. Additionally, the company's inability to advance into other indications and potential long-term dilution risk raise concerns about its financial stability and market position.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.